Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (13339)	3/8/2004 9:10:09 AM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

In2Focus steps up U.K. Pennsaid(R) promotion TORONTO, March 8 /CNW/ - Dimethaid Research Inc. (TSX: DMX) announced today that its specialist sales organization, In2Focus, has negotiated a Co- Funding(TM) agreement with a major international pharmaceutical company. The deal, which takes effect in April 2004, will result in expanding the Pennsaid(R) sales force from 20 to 50 and significantly boosting promotion of the company's anti-arthritic lotion throughout the United Kingdom. Under the agreement, In2Focus will provide the increased support at no additional cost to Dimethaid, other than a slight increase in promotional spending. The expanded team will also detail a non-competing prescription therapy for pulmonary disease. Pennsaid is approved in the U.K. as a treatment for osteoarthritis symptoms in knees and superficial joints, and the two products will be marketed to GPs serving similar patient age groups. "Brokering such a relationship is an example of the added value we provide," said In2Focus chairman, Stephen Kerridge. "Both clients come out ahead, and Pennsaid sales efforts will increase 150 percent." In2Focus provides services to a variety of industry leaders including AstraZeneca, Boehringer-Ingelheim, Eli Lilly and GlaxoSmithKline. "Having made the initial product introductions, this extra sales power becomes the next logical step in our long-range plans for taking Pennsaid to optimum market penetration," said Kerridge. Pennsaid's U.K. sales have grown by an average of more than 30 percent per month since the product launched in October 2003. The topical treatment is positioned to compete against oral nonsteroidal anti-inflammatory drugs in a market estimated at around 356 million pounds sterling annually.

To: Joe Krupa who wrote (13339)	4/26/2004 1:40:53 PM
From: Joe Krupa	Read Replies (3) \| Respond to of 14101

Further to Kimo1's (Ron Nairn) data on this point: - Since December 16 (Provalis arbitration ruling), when the stock moved to the $1.00 level, DMX has traded 33.2 million shares. - DMX has 75.9 million shares outstanding. - Since December 16 (past 4 months and a bit), 43.7% of Dimethaid's outstanding shares have traded hands. Also, since this time, the stock has oscillated around $1.00-1.10. Yes, though we are down 15% over the past few weeks, the stock has been relatively stable since December 16, despite 33.2 million shares being sold. There is obviously interest somewhere.......BUT WHY? Why do the institutional holding's sites really show no change? Who are the new owners of these shares? There's not a chance that's retail buying. There is either a well disguised hostile takeover in the works, or somebody knows something we don't. With DMX in the state it's in (from a public perception point of view), who'd buy 33.2 million shares? I'd be very surprised if retail accounted for even 5 million of that. The mystery continues...